Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
Retrieved on:
Monday, November 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, LR, Population, ART, FDI, University, Disease, Pain, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, CET, Balearic Islands, Wound healing, Foreign direct investment, CHF, Vifor Pharma, Lead, AVS, Chronic kidney disease, Mortality, Calcifying odontogenic cyst, Dialysis, PAD, Cardiovascular disease, CKD, Pharmaceutical industry, Vifor Pharma Group, SNF472, INS-3001, CUA, PAD, AVS, VIFOR PHARMA GROUP, SNF472, INS-3001, CUA, PAD, AVS
53 LR
Key Points:
- 53 LR
Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. - Through these acquisitions, Vifor Pharma will be able to serve a continuum of vascular calcification disorders at all stages of CKD.
- Acquisition of Sanifit is for the continued clinical development and commercialization of SNF472, a novel, first-in-class intravenously administered inhibitor of vascular calcification, for the treatment of CUA and PAD in patients with end-stage kidney disease.
- Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001.